Consequences Escalate If Firms Ignore GMP Compliance Issues
This article was originally published in The Tan Sheet
A warning letter is a firm’s last “real chance” to correct GMP violations without winding up in court, but not the only chance, says FDA attorney Annamarie Kempic. She outlines factors the agency weighs when considering enforcement actions.
You may also be interested in...
Johnson & Johnson CEO Alex Gorsky says bringing recalled OTCs such as Tylenol and Motrin products back to market is the firm’s “clear number one priority” in the near term. J&J also has a timetable for completing its responsibilities under a consent decree with FDA in place since 2011.
Separately, the agency announced in the FR that it is adopting as a final rule a January amendment to the CHD/dietary fiber health claim, which named barley as an additional source of beta-glucan soluble fiber (1"The Tan Sheet" Jan. 2, 2006, In Brief)...
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.